A phase I study of decitabine with pegylated interferon α-2b in advanced melanoma: impact on DNA methylation and lymphocyte populations. | Invest New Drugs;32(5): 969-75, 2014 Oct. | MEDLINE

Main content 1 Search 2 Footer 3

+A A -A High contrast

VHL Regional Portal

Information and Knowledge for Health

Advanced Search EVID@Easy

A phase I study of decitabine with pegylated interferon α-2b in advanced melanoma: impact on DNA methylation and lymphocyte populations.

Plimack, E R; Desai, J R; Issa, J P; Jelinek, J; Sharma, P; Vence, L M; Bassett, R L; Ilagan, J L; Papadopoulos, N E; Hwu, W J.

Affiliation

Plimack ER; Department of Medical Oncology, Fox Chase Cancer Center, Philadelphia, PA, USA, Elizabeth.Plimack@fccc.edu.

Invest New Drugs ; 32(5): 969-75, 2014 Oct.

Article in En | MEDLINE | ID: mdl-24875133

Subject(s)

Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Antineoplastic Combined Chemotherapy Protocols / Melanoma Limits: Aged / Female / Humans / Male / Middle aged Language: En Journal: Invest New Drugs Year: 2014 Document type: Article Country of publication: Estados Unidos

Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Antineoplastic Combined Chemotherapy Protocols / Melanoma Limits: Aged / Female / Humans / Male / Middle aged Language: En Journal: Invest New Drugs Year: 2014 Document type: Article Country of publication: Estados Unidos